Opinion statement
The term vasculitis refers to a pathologic condition defined by inflammatory cell infiltration and destruction of blood vessels. Systemic vasculitis is classified as primary (eg, polyarteritis nodosa, Churg-Strauss syndrome) or secondary, the latter associated with connective tissue disorders, infections, medications, and rarely, as a paraneoplastic phenomenon. Neuropathy is a common complication of systemic vasculitis and is related to ischemic nerve fiber damage with axon loss. Peripheral neuropathy may be the sole manifestation of vasculitis, a condition termed nonsystemic vasculitic neuropathy (NSVN). Treatment of vasculitic neuropathy requires long-term immunosuppressive therapies with potential side effects. The diagnosis of vasculitis should be established by tissue (preferably nerve) biopsy. High-dose prednisone is the standard platform therapy for patients with systemic and NSVN; for those with systemic vasculitis, at least 3 to 12 months of treatment with cyclophosphamide (monthly intravenous pulse or daily oral therapy) is also necessary to sustain remission and allow successful prednisone tapering. The use of cyclophosphamide in patients with NSVN is controversial, but recent retrospective data suggest that those treated with prednisone and cyclophosphamide from the outset fare better than those initially treated only with prednisone. If prednisone is administered as monotherapy, cyclophosphamide should be added after several months if there is no improvement or relapse occurs with tapering of prednisone. Intravenous pulse and daily oral cyclophosphamide probably offer similar efficacy, although the risk of complications is greater with oral therapy. Azathioprine can be safely substituted for cyclophosphamide after 3 months without an increased relapse rate. Azathioprine, methotrexate, intravenous immune globulin, mycophenolate mofetil, plasma exchange, and rituximab can be offered to patients who are intolerant or have a contraindication to cyclophosphamide. However, efficacy is unproven for any of these therapies. Interferon-α, sometimes combined with plasma exchange, is used to treat vasculitis associated with hepatitis B infection. Some patients also may improve with corticosteroids. The classification of diabetic lumbosacral radiculoplexus neuropathy as a vasculitic disorder remains controversial. However, there is compelling pathological evidence that this condition represents a T-cell-mediated microvasculitis. Some patients treated with intravenous corticosteroids may have greater recovery and improved pain control.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Jennette JC, Falk AJ, Andrassy K, et al.: Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994, 37:187–192.
Bradley WG, Chad D, Verghese JP, et al.: Painful lumbosacral plexopathy with elevated erythrocyte sedimentation rate: a treatable inflammatory syndrome. Ann Neurol 1984, 15:457–464.
Dyck PJ, Engelstad J, Norell J, Dyck PJ: Microvasculitis in non-diabetic lumbosacral radiculoplexus neuropathy (LSRPN): similarity to the diabetic variety (DLSRPN). J Neuropathol Exp Neurol 2000, 59:525–538.
Dyck PJ, Windebank AJ: Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002, 25:477–491.
Collins MP, Kissel JT: Vasculitis of the peripheral nervous system. In Neurological Therapeutics: Principles and Practice. Edited by Noseworthy JH. London: Martin Dunitz; 2003:2078–2110.
Wees SJ, Sunwoo IN, Oh SJ: Sural nerve biopsy in systemic necrotizing vasculitis. Am J Med 1981, 71:525–532.
Seo JH, Ryan HF, Claussen GC, et al.: Sensory neuropathy in vasculitis: a clinical, pathologic, and electrophysiologic study. Neurology 2004, 63:874–878.
Said G, Lacroix C: Primary and secondary vasculitic neuropathy. J Neurol 2005, 252:633–641.
Chia L, Fernandez A, Lacroix C, et al.: Contribution of nerve biopsy findings to the diagnosis of disabling neuropathy in the elderly. A retrospective review of 100 consecutive patients. Brain 1996, 119:1091–1098.
Rosenbaum R: Neuromuscular complications of connective tissue diseases. Muscle Nerve 2001, 24:154–169. Excellent review of the various peripheral nervous system complications associated with connective tissue disorders.
Puechal X, Said G, Hilliquin P, et al.: Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 1995, 38:1618–1629.
Khella SL, Frost S, Hermann GA, et al.: Hepatitis C infection, cryoglobulinemia, and vasculitic neuropathy. Treatment with interferon alfa: case report and literature review. Neurology 1995, 45:407–411.
Said G, Lacroix C, Plante-Bordeneuve V, et al.: Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinicopathological study of 11 patients. Brain 2002, 125:264–275.
McCombe PA, McLead JG, Pollard JD, et al.: Peripheral sensorimotor and autonomic neuropathy associated with systemic lupus erythematosus. Clinical, pathological, and immunological features. Brain 1987, 110:533–549.
Mori K, Iijima M, Koike H, et al.: The wide spectrum of clinical manifestations in Sjogren’s syndromeassociated neuropathy. Brain 2005, 128:2518–2534.
Guillevin L, Lhote F, Cohen P, et al.: Polyarteritis nodosa related to hepatitis B virus: a prospective study with long-term observation of 41 patients. Medicine 1995, 74:238–253.
Cohen JA, Wilborn SL, Rector WG Jr, Golitz LE: Mononeuropathy multiplex associated with acute hepatitis B infection. Muscle Nerve 1990, 13:195–198.
Nemni R, Sanvito L, Quattrini A, et al.: Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. J Neurol Neurosurg Psychiatry 2003, 74:1267–1271.
Kanai K, Kuwabara S, Mori M, et al.: Leukocytoclasticvasculitic neuropathy associated with chronic Epstein-Barr virus infection. Muscle Nerve 2003, 27:113–116.
Somer T, Finegold SM: Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis 1995, 20:1010–1036.
Bradley WG, Verma A: Painful vasculitic neuropathy in HIV-1 infection: relief of pain with prednisone therapy. Neurology 1996, 47:1446–1451.
Ferrari S, Lanzafame M, Faggian F, et al.: Painful neuropathy vasculitis in 2 patients with long-standing human immunodeficiency virus-1 infection. Scand J Infect Dis 2004, 36:392–393.
Oh SJ: Paraneoplastic vasculitis of the peripheral nervous system. Neurol Clin 1997, 15:849–863.
Doyle MK, Cuellar ML: Drug-induced vasculitis. Expert Opin Drug Saf 2003, 2:401–409.
Bouche P, Leger JM, Travers MA, et al.: Peripheral neuropathy in systemic vasculitis: clinical and electrophysiologic study of 22 patients. Neurology 1986, 36:1598–1602.
Olney RK: Neuropathies associated with connective tissue disease. Semin Neurol 1998, 18:63–72.
Briemberg HR, Levin K, Amato AA: Multifocal conduction block in peripheral nerve vasculitis. J Clin Neuromusc Dis 2002, 3:153–158.
Kissel JT, Collins MP, Mendell JR: Vasculitic neuropathy. In Diagnosis and Management of Peripheral Nerve Disorders. Edited by Mendell JR, Kissel JT, Cornblath DR. New York: Oxford University Press; 2001:202–232.
Collins MP, Mendell JR, Periquet MI, et al.: Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy.Neurology 2000, 55:636–643.
Pagnoux C, Guillevin L: Peripheral neuropathy in systemic vasculitides.Curr Opin Rheumatol 2005, 17:41–48.
Collins MP, Periquet MI: Nonsystemic vasculitic neuropathy.Curr Opin Neurol 2004, 17:587–598.
Kararizou E, Davaki P, Karandreas N, et al.: Nonsystemic vasculitic neuropathy: a clinicopathological study of 22 cases.J Rheumatol. 2005, 32:853–858.
Collins MP, Periquet MI, Mendell JR, et al.: Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology 2003, 61:623–630. This excellent retrospective study characterizes the clinical features and treatment response in a large series of patients with NSVN.
Dyck PJB, Norell JE, Dyck PJ: Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy.Neurology 1999, 53:2113–2121. This study provides compelling evidence for a microvasculitis as the primary pathology of DLSRPN.
Kelkar P, Masood M, Parry GJ: Distinctive pathologic findings in proximal diabetic neuropathy (diabetic amyotrophy). Neurology 2000, 55:83–88.
Said G, Lacroix C, Lozeron P, et al.: Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain 2003, 126:376–385.
Llewelyn JG, Thomas PK, King RH: Epineurial microvasculitis in proximal diabetic neuropathy. J Neurol 1998, 245:159–165.
Adu D, Pall A, Luqmani RA, et al.: Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of vasculitis. Q J Med 1997, 90:401–409.
Guillevin L, Cordier JF, Lhote F, et al.: A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis.Arthritis Rheum 1997, 40:2187–2198.
Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with anti-neutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:36–44.
Levy Y, Uziel Y, Zandman GG, et al.: Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis.Ann Rheum Dis 2003, 62:1221–1223.
Tsurikisawa N, Taniguchi M, Saito H, et al.: Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin.Ann Allergy Asthma Immunol 2004, 92:80–87.
Zaja F, De Vita S, Mazzaro C, et al.: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003, 101:3827–3834.
Uthman I: Pharmacological therapy of vasculitis: an update. Curr Opin Pharmacol 2004, 4:177–182.
Mang R, Ruzicka T, Stege H: Therapy for severe necrotizing vasculitis with infliximab. J Am Acad Dermatol 2004, 51:321–322.
Chandesris MO, Gayet S, Schleinitz N, et al.: Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia. Rheumatology 2004, 43:532–533.
Hellmich B, Gross WL: Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 2004, 5:25–35.
Pockros PJ, Carithers R, Desmond P, et al.: PEGASYS International Study Group. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004, 99:1298–1305.
Mazzaro C, Zorat F, Caizzi M, et al.: Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005, 42:632–638.
Boonyapisit K, Katirji B: Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 2002, 25:909–913.
Valbonesi M, Montani F, Mosconi L, et al.: Plasmapheresis and cytotoxic drugs for mixed cryoglobulinemia. Haematologia 1984, 17:341–351.
Wulff EA, Wang AK, Simpson DM: HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 2000, 59:1251–1260.
Dyck PJ, Benstead TJ, Conn DL, et al.: Nonsystemic vasculitic neuropathy. Brain 1987, 110:843–853.
Griffin JW: Vasculitic neuropathies. Rheum Dis Clin North Am 2001, 27:751–760.
Krendel DA, Zacharias A, Younger DS: Autoimmune diabetic neuropathy. Neurol Clin 1997, 15:959–971.
Pascoe MK, Low PA, Windebank AJ, Litchy WJ: Subacute diabetic proximal neuropathy. Mayo Clin Proc 1997, 72:1123–1132.
Kilfoyle D, Kelkar P, Parry GJ: Pulsed methylprednisolone is safe and effective treatment for diabetic amyotrophy. J Clin Neuromusc Dis 2003, 4:168–170.
Dyck PJB, O’Bri0en PC, Bosch EP, et al.: Results of a controlled trial of IV methylprednisolone in diabetic lumbosacral radiculoplexus neuropathy (DLRPN): a preliminary indication of efficacy. J Peripher Nerv Syst 2005, 10(Suppl 1):21.
De Groot K, Rasmussen N, Bacon PA, et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:2461–2469.
Guillevin L, Mahr A, Cohen P, et al.: Vasculitis Study Group. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virusrelated polyarteritis nodosa. Arthritis Rheum 2004, 51:482–487.
Murai H, Inaba S, Kira J, et al.: Hepatitis C virus associated cryoglobulinemic neuropathy successfully treated with plasma exchange. Artif Organs 1995, 19:334–338.
Gorson KC, Amato AA, Ropper AH: Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004, 63:715–717.
Nowack R, Gobel U, Klooker P, et al.: Mycophenolate mofetil for maintenance therapy of Wegener’s granulomatous and microscopic polyangiitis: a pilot study of 11 patients with renal involvement. J Am Soc Nephrol 1999, 10:1965–1971.
Langford CA, Talar-Williams C, Sneller MC: Mycophenolate mofetil for remission maintenance in the treatment of Wegener’s granulomatosis. Arthritis Rheum 2004, 51:278–283.
Chambers SA, Isenberg D: Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 2005, 14:210–214.
Renaud S, Gregor M, Fuhr P, et al.: Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003, 27:611–615.
Eriksson P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005, 257:540–548.
Omdal R, Wildhagen K, Hansen T, et al.: Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response. Scand J Rheumatol 2005, 34:229–232.
Lamprecht P, Lerin-Lozano C, Merz H, et al.: Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2003, 62:1230–1233.
Booth A, Harper L, Hammad T, et al.: Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004, 15:717–721.
van der Bijl AE, Allaart CF, Van Vugt J, et al.: Rheumatoid vasculitis treated with infliximab. J Rheumatol 2005, 32:1607–1609.
Al-Bishri J, le Riche N, Pope JE: Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 2005, 32:1371–1373.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gorson, K.C. Therapy for Vasculitic Neuropathies. Curr Treat Options Neurol 8, 105–117 (2006). https://doi.org/10.1007/s11940-006-0002-1
Issue Date:
DOI: https://doi.org/10.1007/s11940-006-0002-1